Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flunarizine - Xenon Pharmaceuticals

Next Previous
Drug Profile

Flunarizine - Xenon Pharmaceuticals

Alternative Names: XEN 007

Latest Information Update: 15 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Piperazines; Sedating antihistamines; Vascular disorder therapies
  • Mechanism of Action Calcium channel antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Migraine; Hemiplegia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Absence epilepsy
  • No development reported Migraine

Most Recent Events

  • 29 Nov 2023 University of British Columbia terminates phase II trial in Absence epilepsy (In children, Adjunctive treatment, Treatment-resistant, In adolscents) in Canada (PO) because the enrollment wasn't as predicted and there were not enough numbers to show statistical significance (NCT06153186)
  • 28 Feb 2021 No recent reports of development identified for phase-I development in Migraine in Canada
  • 31 Dec 2020 Xenon Pharmaceuticals has patents pending for XEN 007 in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top